# ABBV earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ABBV) · [Earnings tab](https://www.lopjlb.com/stock/ABBV?tab=earnings)

Updated: 2026-07-20T02:12:19

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight quarterly calls AbbVie’s story shifts from early optimism about immunology growth to a more nuanced picture where strong Skyrizi and Rinvoq performance coexists with accelerating Humira biosimilar erosion and persistent macro‑economic headwinds in aesthetics. Management tone remains broadly upbeat (≈0.8) despite a dip to 0.6 in Q1 2026, while guidance has been repeatedly raised, reflecting confidence in the ex‑Humira franchise. Biosimilar pressure on Humira deepens, with operational declines moving from ~29% in Q2 2024 to over 58% by Q2 2025, prompting recurring concerns. Economic softness in China and inflation‑driven consumer restraint continue to dampen aesthetics sales. The company expands capital commitments, unveiling a $10 bn‑plus investment plan and a decade‑long $100 bn R&D pledge, alongside multiple acquisitions (Cerevel, Capstan). Regulatory execution improves, delivering several approvals (Skyrizi UC, Epkinly, Elahere, EMRELIS) while new milestones (Rinvoq GCA, Teliso‑V) remain pending. Emerging risks include IRA pricing negotiations, trade‑tariff exposure, and manufacturing execution challenges, adding layers to the forward outlook.

## Latest CallCard · Q1

AbbVie Q1 2026 beat revenue and EPS expectations, raised full‑year EPS guidance, highlighted strong immunology and neuroscience sales, and outlined multiple pipeline advances and manufacturing investments.

**Guidance:** raised — raised full‑year adjusted EPS guidance by $0.12 to $14.08‑$14.28

**Tone:** mgmt 0.6 · Q&A pressure 0.5 · divergence 0.2

management highlighted strong revenue growth, raised EPS guidance, and emphasized pipeline progress and new manufacturing investments

### Demand visibility

Strong demand across immunology, neuroscience and oncology

Immunology sales grew 12.4% with Skyrizi and Rinvoq outperforming; neuroscience up 24.3%; oncology modest decline but Venclexta solid

### Margins / costs

Margins remain high

Adjusted gross margin was 83.6% of sales in Q1 and full‑year forecast above 84%; R&D expense 15.1% of sales

### Capital allocation

Investing in manufacturing sites and pipeline

$1.4B North Carolina pharma campus, $380M two new North Chicago plants, $100B 10‑year R&D commitment, and continued dividend returns

### Milestones

- **Rinvoq alopecia areata regulatory submission** [new]: submitted to FDA; decision anticipated later this year in Europe/Japan and early 2027 in the U.S
- **Skyrizi subcutaneous induction approval decision** [on_track]: U.S. regulatory application submitted; approval decision expected later this year
- **ABBV‑295 obesity early‑stage study** [delivered]: Multiple ascending dose study showed ~10% weight loss in 12 weeks with favorable safety
- **Remagen PD‑1/VEGF bispecific agreement** [new]: Closed agreement to add novel bispecific antibody to emerging oncology pipeline
- **North Carolina manufacturing campus construction** [on_track]: $1.4B investment to build new pharma manufacturing campus
- **North Chicago new plants construction** [on_track]: $380M investment for two new manufacturing sites
- **Skyrizi + ABBV‑382 combo Phase III planning** [at_risk]: Phase III expected in ~2 years; dose‑escalation work ongoing
- **Extended half‑life IL‑23 ABB‑547 first‑in‑human** [on_track]: First‑in‑human study slated for this year

### Fears / risks

- **Competitive pressure**: Skyrizi faces upcoming oral competitors and biosimilar pressure on HUMIRA
- **Regulatory uncertainty**: Pending FDA decisions for Rinvoq alopecia, Skyrizi sub‑Q induction, and obesity asset
- **Manufacturing execution risk**: Construction of new manufacturing campuses could encounter cost or schedule overruns
- **Clinical development risk**: Combo programs (Skyrizi+ABBV‑382) and IRAK4 oral candidate may not meet efficacy endpoints
- **Economic headwinds**: Aesthetics market shows modest growth and pricing pressure amid inflation
- **Biosimilar impact**: HUMIRA sales down 40% due to biosimilar competition
- **Labeling and safety**: Discussions with FDA on revised Skyrizi tuberculosis monitoring language
- **Pipeline timing**: Several Phase III readouts scheduled for 2026‑2027 could affect future growth

### Key quotes

> “We achieved adjusted earnings per share of $2.65, which is $0.07 above our guidance midpoint.”

> “Skyrizi total sales were $4.5 billion, up 29.2% on an operational basis, exceeding our expectations.”

> “We are extremely pleased with the strong performance demonstrated by subcutaneous reduction, especially considering that this study enrolled a very difficult-to-treat patient population.”

## Quarter one-liners

- **2026 Q1:** AbbVie Q1 2026 beat revenue and EPS expectations, raised full‑year EPS guidance, highlighted strong immunology and neuroscience sales, and outlined multiple pipeline advances and manufacturing investments.
- **2025 Q4:** AbbVie reports record Q4 2025 sales, strong growth in SKYRIZI and RINVOQ, and expects 9.5% sales rise in 2026 despite HUMIRA erosion and IMBRUVICA pricing pressure.
- **2025 Q3:** AbbVie Q3 2025 beat expectations, raised full‑year outlook, saw strong immunology and neuroscience growth, pipeline progress, but faces macro pressure in aesthetics and ongoing Humira erosion.
- **2025 Q2:** AbbVie beat Q2 expectations, raised full‑year revenue and EPS guidance, highlighted strong Skyrizi/Rinvoq growth, new approvals and pipeline progress, while noting biosimilar, tariff and pricing uncertainties.
- **2025 Q1:** AbbVie Q1 2025 beat earnings and revenue expectations, raised full‑year EPS guidance, and highlighted strong immunology, oncology and neuroscience sales alongside an advancing pipeline.
- **2024 Q4:** AbbVie reports strong Q4 2024 results driven by ex‑Humira growth, robust Skyrizi/Rinvoq performance and new approvals, while noting economic headwinds in aesthetics and upcoming regulatory milestones.
- **2024 Q3:** AbbVie reports double‑digit growth from its ex‑Humira platform, raises full‑year revenue and EPS guidance, completes Cerevel acquisition and highlights strong Skyrizi, Rinvoq and neuroscience momentum while noting pricing headwinds in aesthetics and pending emraclidine data.
- **2024 Q2:** AbbVie reports strong Q2 revenue growth driven by immunology and oncology, raises guidance, but notes biosimilar pressure on Humira, economic headwinds in China and regulatory/political uncertainties.

## Theme arcs

- **Humira biosimilar erosion** (deteriorating): Operational sales down from 28.9% to 58.2% across calls
- **Immunology growth (Skyrizi/Rinvoq)** (improving): Robust sales, multiple approvals and expanding indications
- **Aesthetics market headwinds** (deteriorating): Economic slowdown in China and inflation suppressing consumer spending
- **Capital investment expansion** (new): $10 bn plan announced 2025 Q2 and $100 bn decade‑long R&D pledge 2026 Q4
- **Regulatory milestone execution** (improving): Several approvals delivered; pending assets tracked
- **Management tone stability** (stable): Tone scores hover around 0.8, slight dip to 0.6 in 2026 Q1
- **Pricing pressure (IRA, IMBRUVICA)** (deteriorating): IRA negotiations surface 2025 Q4, IMBRUVICA pricing risk noted 2026 Q4
- **Trade tariff risk** (new): First mentioned 2025 Q2 with EU tariff investigation
- **Macro‑economic uncertainty** (stable): Continues to affect guidance and aesthetics outlook
- **Manufacturing execution risk** (new): Construction of new US campuses flagged 2026 Q1

## Guidance path

2024 Q2:raised → 2024 Q3:raised → 2024 Q4:raised → 2025 Q1:raised → 2025 Q2:raised → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:raised

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ABBV`